

# Glenn Chertow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6031900/publications.pdf>

Version: 2024-02-01

583  
papers

67,201  
citations

1238

110  
h-index

834

245  
g-index

594  
all docs

594  
docs citations

594  
times ranked

42243  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. <i>New England Journal of Medicine</i> , 2004, 351, 1296-1305.	27.0	9,843
2	Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3365-3370.	6.1	2,887
3	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	27.0	2,523
4	Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2208-2218.	6.1	2,350
5	Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2008, 359, 7-20.	27.0	1,611
6	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. <i>Kidney International</i> , 2002, 62, 245-252.	5.2	1,316
7	Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2010, 362, 590-599.	27.0	1,023
8	Cardiac calcification in adult hemodialysis patients. <i>Journal of the American College of Cardiology</i> , 2002, 39, 695-701.	2.8	1,020
9	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2673.	7.4	991
10	In-Center Hemodialysis Six Times per Week versus Three Times per Week. <i>New England Journal of Medicine</i> , 2010, 363, 2287-2300.	27.0	898
11	Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. <i>Kidney International</i> , 2009, 76, 422-427.	5.2	888
12	Functional Status of Elderly Adults before and after Initiation of Dialysis. <i>New England Journal of Medicine</i> , 2009, 361, 1539-1547.	27.0	849
13	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2492-2503.	27.0	844
14	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	27.0	805
15	Spectrum of acute renal failure in the intensive care unit: The PICARD experience. <i>Kidney International</i> , 2004, 66, 1613-1621.	5.2	763
16	Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2134-2140.	6.1	614
17	Diuretics, Mortality, and Nonrecovery of Renal Function in Acute Renal Failure. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2547.	7.4	604
18	The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S148-S153.	6.1	545

#	ARTICLE	IF	CITATIONS
19	Significance of Frailty among Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2960-2967.	6.1	545
20	Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. <i>Kidney International</i> , 2005, 68, 1793-1800.	5.2	499
21	Declining Mortality in Patients with Acute Renal Failure, 1988 to 2002. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1143-1150.	6.1	499
22	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1327-1339.	0.7	491
23	Effects of Phosphate Binders in Moderate CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1407-1415.	6.1	486
24	Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. <i>Kidney International</i> , 2009, 76, 893-899.	5.2	483
25	Acute Renal Failure Definitions and Classification. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2178-2187.	6.1	463
26	Community-based incidence of acute renal failure. <i>Kidney International</i> , 2007, 72, 208-212.	5.2	461
27	The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. <i>Kidney International</i> , 2011, 80, 1080-1091.	5.2	450
28	The risk of acute renal failure in patients with chronic kidney disease. <i>Kidney International</i> , 2008, 74, 101-107.	5.2	448
29	Octogenarians and Nonagenarians Starting Dialysis in the United States. <i>Annals of Internal Medicine</i> , 2007, 146, 177.	3.9	446
30	Diagnosis, Epidemiology and Outcomes of Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 844-861.	4.5	431
31	Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1688-1694.	6.1	415
32	Update on adverse drug events associated with parenteral iron. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 378-382.	0.7	405
33	Acute Kidney Injury and Mortality in Hospitalized Patients. <i>American Journal of Nephrology</i> , 2012, 35, 349-355.	3.1	399
34	Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. <i>New England Journal of Medicine</i> , 2018, 378, 603-614.	27.0	399
35	Cognitive Impairment in Chronic Kidney Disease. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1863-1869.	2.6	380
36	Effects of Intensive BP Control in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2812-2823.	6.1	364

#	ARTICLE	IF	CITATIONS
37	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2018, 71, 851-865.	1.9	362
38	Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. <i>Critical Care</i> , 2010, 14, R82.	5.8	342
39	Refining Predictive Models in Critically Ill Patients with Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1350-1357.	6.1	328
40	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	27.0	310
41	Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 173-179.	1.6	300
42	Timing of Initiation of Dialysis in Critically Ill Patients with Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 915-919.	4.5	299
43	Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. <i>Kidney International</i> , 2005, 67, 760-771.	5.2	290
44	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 22-31.	11.4	287
45	Renalism. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2462-2468.	6.1	281
46	Frailty and Chronic Kidney Disease: The Third National Health and Nutrition Evaluation Survey. <i>American Journal of Medicine</i> , 2009, 122, 664-671.e2.	1.5	279
47	PTH and the Risks for Hip, Vertebral, and Pelvic Fractures Among Patients on Dialysis. <i>American Journal of Kidney Diseases</i> , 2006, 47, 149-156.	1.9	271
48	Frailty, Dialysis Initiation, and Mortality in End-Stage Renal Disease. <i>Archives of Internal Medicine</i> , 2012, 172, 1071-7.	3.8	267
49	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.	1.6	259
50	Determinants of progressive vascular calcification in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1489-1496.	0.7	258
51	Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. <i>Lancet</i> , 2020, 396, 1335-1344.	13.7	257
52	Association of body size with outcomes among patients beginning dialysis. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 324-332.	4.7	248
53	Mortality after acute renal failure: Models for prognostic stratification and risk adjustment. <i>Kidney International</i> , 2006, 70, 1120-1126.	5.2	245
54	Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. <i>Intensive Care Medicine</i> , 2011, 37, 241-248.	8.2	239

#	ARTICLE	IF	CITATIONS
55	Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients.. Journal of the American Society of Nephrology: JASN, 1995, 6, 75-81.	6.1	236
56	Health-related quality of life and estimates of utility in chronic kidney disease. Kidney International, 2005, 68, 2801-2808.	5.2	235
57	Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal, 2005, 149, 820-825.	2.7	225
58	Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease. Kidney International, 2001, 59, 1121-1127.	5.2	214
59	Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. JAMA - Journal of the American Medical Association, 2017, 317, 156.	7.4	213
60	Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2006, 21, 2543-2548.	0.7	198
61	Cystatin C and Mortality Risk in the Elderly. Journal of the American Society of Nephrology: JASN, 2006, 17, 254-261.	6.1	195
62	Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group.. Journal of the American Society of Nephrology: JASN, 1998, 9, 692-698.	6.1	190
63	Effect of frequent hemodialysis on residual kidney function. Kidney International, 2013, 83, 949-958.	5.2	186
64	Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. Circulation, 2004, 110, 3667-3673.	1.6	185
65	Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney International, 2001, 60, 333-340.	5.2	182
66	Estimating the Risk of Radiocontrast-Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 653-659.	6.1	182
67	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 2021, 100, 215-224.	5.2	182
68	Chronic Kidney Disease and Functional Limitation in Older People: Health, Aging and Body Composition Study. Journal of the American Geriatrics Society, 2006, 54, 750-756.	2.6	177
69	Frequent Hemodialysis Network (FHN) randomized trials: Study design. Kidney International, 2007, 71, 349-359.	5.2	176
70	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 274-282.	0.7	168
71	An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard. Value in Health, 2009, 12, 80-87.	0.3	166
72	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1466-1475.	6.1	163

#	ARTICLE	IF	CITATIONS
73	Cost of Acute Kidney Injury in Hospitalized Patients. <i>Journal of Hospital Medicine</i> , 2017, 12, 70-76.	1.4	162
74	Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. <i>Kidney International</i> , 2017, 92, 238-247.	5.2	158
75	The Severity of Secondary Hyperparathyroidism in Chronic Renal Insufficiency is GFR-Dependent, Race-Dependent, and Associated with Cardiovascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2762-2769.	6.1	157
76	Chronic kidney disease and cognitive impairment in menopausal women. <i>American Journal of Kidney Diseases</i> , 2005, 45, 66-76.	1.9	152
77	Control of Hypertension in Adults With Chronic Kidney Disease in the United States. <i>Hypertension</i> , 2005, 45, 1119-1124.	2.7	151
78	Acute renal failure after endovascular vs open repair of abdominal aortic aneurysm. <i>Journal of Vascular Surgery</i> , 2006, 43, 460-466.e2.	1.1	151
79	Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 2533-2539.	1.6	147
80	Low level of self-reported physical activity in ambulatory patients new to dialysis. <i>Kidney International</i> , 2010, 78, 1164-1170.	5.2	146
81	Suicide in the United States End-Stage Renal Disease Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 774-781.	6.1	144
82	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 898-905.	4.5	144
83	Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis. , 2015, 25, 351-356.		141
84	Risks for End-Stage Renal Disease, Cardiovascular Events, and Death in Hispanic versus Non-Hispanic White Adults with Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2892-2899.	6.1	140
85	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	1.7	139
86	Effects of Frequent Hemodialysis on Measures of CKD Mineral and Bone Disorder. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 727-738.	6.1	137
87	Risk prediction models for contrast induced nephropathy: systematic review. <i>BMJ, The</i> , 2015, 351, h4395.	6.0	137
88	Vadadustat in Patients with Anemia and Non-dialysis-Dependent CKD. <i>New England Journal of Medicine</i> , 2021, 384, 1589-1600.	27.0	137
89	Analgesia in patients with ESRD: a review of available evidence. <i>American Journal of Kidney Diseases</i> , 2003, 42, 217-228.	1.9	136
90	On the relative safety of parenteral iron formulations. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1571-1575.	0.7	136

#	ARTICLE	IF	CITATIONS
91	Association between Body Composition and Frailty among Prevalent Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 381-389.	6.1	134
92	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. <i>Circulation</i> , 2018, 137, 134-143.	1.6	134
93	Decrease in Thoracic Vertebral Bone Attenuation With Calcium-Based Phosphate Binders in Hemodialysis. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 764-772.	2.8	132
94	Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury*. <i>Critical Care Medicine</i> , 2007, 35, 2755-2761.	0.9	131
95	Characterizing Frailty Status in the Systolic Blood Pressure Intervention Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 649-655.	3.6	131
96	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2015, 162, 258-265.	3.9	128
97	Randomized trial of intravenous iron-induced hypophosphatemia. <i>JCI Insight</i> , 2018, 3, .	5.0	127
98	Suspected iron dextran-related adverse drug events in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2001, 37, 743-749.	1.9	126
99	Hip Fracture in Patients With Non-Dialysis-Requiring Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1803-1809.	2.8	123
100	Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. <i>American Journal of Nephrology</i> , 2018, 47, 40-47.	3.1	123
101	Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 146.	7.4	122
102	Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 315-322.	4.5	122
103	Factors Associated with Frailty and Its Trajectory among Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1100-1108.	4.5	120
104	Serum Blood Urea Nitrogen as an Independent Marker of Subsequent Mortality Among Patients With Acute Coronary Syndromes and Normal to Mildly Reduced Glomerular Filtration Rates. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1781-1786.	2.8	117
105	Association of Physical Activity with Survival among Ambulatory Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 248-253.	4.5	117
106	A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5. <i>American Journal of Kidney Diseases</i> , 2015, 65, 728-736.	1.9	117
107	Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2765-2774.	0.7	115
108	The Phosphate Binder Equivalent Dose. <i>Seminars in Dialysis</i> , 2011, 24, 41-49.	1.3	114

#	ARTICLE	IF	CITATIONS
109	Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. <i>International Journal of Cancer</i> , 2014, 134, 2245-2252.	5.1	114
110	How to Sustain Change and Support Continuous Quality Improvement. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 916-924.	4.5	110
111	A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. <i>Clinical Nephrology</i> , 1999, 51, 18-26.	0.7	110
112	Systematic evaluation of environmental and behavioural factors associated with all-cause mortality in the United States National Health and Nutrition Examination Survey. <i>International Journal of Epidemiology</i> , 2013, 42, 1795-1810.	1.9	109
113	Insulin resistance in critically ill patients with acute renal failure. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, F259-F264.	2.7	108
114	The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 800-807.	4.5	107
115	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.7	107
116	Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 260-267.	6.1	106
117	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 384, 1601-1612.	27.0	106
118	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EVALUATION Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001363.	3.7	105
119	Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 290-295.	6.7	104
120	How to Begin a Quality Improvement Project. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 893-900.	4.5	104
121	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2018, 71, 352-361.	1.9	104
122	Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis. <i>Circulation</i> , 2020, 141, 728-739.	1.6	104
123	Racial Ethnic Differences in Rates and Determinants of Deceased Donor Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 743-751.	6.1	103
124	Effluent Volume in Continuous Renal Replacement Therapy Overestimates the Delivered Dose of Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 467-475.	4.5	100
125	Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. <i>American Journal of Hematology</i> , 2018, 93, 683-690.	4.1	100
126	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. <i>Kidney International Reports</i> , 2021, 6, 1775-1787.	0.8	100



#	ARTICLE	IF	CITATIONS
127	Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. <i>Kidney International</i> , 2004, 66, 1266-1271.	5.2	99
128	Cystatin C and Measures of Physical Function in Elderly Adults: The Health, Aging, and Body Composition (HABC) Study. <i>American Journal of Epidemiology</i> , 2006, 164, 1180-1189.	3.4	99
129	The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2003, 23, 307-314.	3.1	98
130	Weekend Hospital Admission, Acute Kidney Injury, and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 845-851.	6.1	97
131	Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 102-107.	0.7	97
132	Survival by Dialysis Modality in Critically Ill Patients with Acute Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3132-3138.	6.1	95
133	Infection-Related Hospitalizations in Older Patients With ESRD. <i>American Journal of Kidney Diseases</i> , 2010, 56, 522-530.	1.9	95
134	Effects of Six versus Three Times per Week Hemodialysis on Physical Performance, Health, and Functioning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 782-794.	4.5	95
135	Targeting Vascular Calcification in Chronic Kidney Disease. <i>JACC Basic To Translational Science</i> , 2020, 5, 398-412.	4.1	95
136	Metabolic and Monetary Costs of Avoidable Parenteral Nutrition Use. <i>Journal of Parenteral and Enteral Nutrition</i> , 1999, 23, 109-113.	2.6	94
137	Prevention of Contrast-Induced AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1618-1631.	4.5	94
138	Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. <i>American Journal of Kidney Diseases</i> , 2015, 66, 459-468.	1.9	93
139	Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2311-2318.	0.7	92
140	Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1851-1858.	6.1	92
141	Screening Rates for Primary Aldosteronism in Resistant Hypertension. <i>Hypertension</i> , 2020, 75, 650-659.	2.7	92
142	Preexisting Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1914-1919.	4.5	91
143	Long-Term Effects of Frequent In-Center Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1830-1836.	6.1	91
144	Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2435-2438.	6.1	91

#	ARTICLE	IF	CITATIONS
145	The Case against Calcium-Based Phosphate Binders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 697-703.	4.5	89
146	Kidney dysfunction and fatal cardiovascular disease— an association independent of atherosclerotic events: Results from the Health, Aging, and Body Composition (Health ABC) study. <i>American Heart Journal</i> , 2008, 155, 62-68.	2.7	89
147	Model to Predict Mortality in Critically Ill Adults with Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2114-2120.	4.5	88
148	Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1663-1673.	6.1	88
149	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2352-2361.	6.1	88
150	Determinants of Left Ventricular Mass in Patients on Hemodialysis. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 251-261.	2.6	87
151	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
152	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 743-754.	11.4	87
153	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 755-766.	11.4	86
154	Burden on caregivers as perceived by hemodialysis patients in the Frequent Hemodialysis Network (FHN) trials. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2316-2322.	0.7	85
155	Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma. <i>Urology</i> , 2014, 83, 774-780.	1.0	85
156	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
157	Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis. <i>American Journal of Nephrology</i> , 2015, 42, 134-140.	3.1	84
158	Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 641-652.	6.1	83
159	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	3.1	82
160	Trends in Acute Kidney Injury, Associated Use of Dialysis, and Mortality After Cardiac Surgery, 1999 to 2008. <i>Annals of Thoracic Surgery</i> , 2013, 95, 20-28.	1.3	82
161	Physician Visits and 30-Day Hospital Readmissions in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2079-2087.	6.1	82
162	Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. <i>Kidney International</i> , 2010, 77, 637-644.	5.2	81

#	ARTICLE	IF	CITATIONS
163	Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 555-563.	11.4	81
164	Association of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality among Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 626-632.	4.5	80
165	Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1260-1267.	4.5	80
166	Sarcopenia among patients receiving hemodialysis: weighing the evidence. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 57-68.	7.3	80
167	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. <i>Journal of the American Heart Association</i> , 2018, 7, e009326.	3.7	79
168	Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1933-1942.	6.1	78
169	Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis. <i>Kidney International</i> , 2017, 91, 746-754.	5.2	78
170	Ongoing Clinical Trials in AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 861-873.	4.5	76
171	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic) Tj ETQq1 1 0.784314 rgBT /Overlock	2.7	76
172	Comparison of Self-report-Based and Physical Performance-Based Frailty Definitions Among Patients Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2014, 64, 600-607.	1.9	75
173	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.	4.5	75
174	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 1216-1227.	2.2	75
175	Phosphorus balance and mineral metabolism with 3h daily hemodialysis. <i>Kidney International</i> , 2007, 71, 336-342.	5.2	72
176	Effects of Selonsertib in Patients with Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1980-1990.	6.1	72
177	Causes of Death after a Hospitalization with AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1001-1010.	6.1	71
178	Effects of Frequent Hemodialysis on Ventricular Volumes and Left Ventricular Remodeling. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2106-2116.	4.5	70
179	Temporal Trends in the Incidence, Treatment and Outcomes of Hip Fracture After First Kidney Transplantation in the United States. <i>American Journal of Transplantation</i> , 2014, 14, 943-951.	4.7	70
180	Sensitization from transfusion in patients awaiting primary kidney transplant. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2908-2918.	0.7	69

#	ARTICLE	IF	CITATIONS
181	Rehospitalizations and Emergency Department Visits after Hospital Discharge in Patients Receiving Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3141-3150.	6.1	69
182	Cystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study. <i>Journal of Cardiac Failure</i> , 2006, 12, 601-607.	1.7	68
183	Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. <i>Kidney International</i> , 2010, 77, 630-636.	5.2	68
184	Fetuin-A and kidney function in persons with coronary artery disease—data from the heart and soul study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2144-2151.	0.7	67
185	Temporal Trends in the Incidence, Treatment, and Outcomes of Hip Fracture in Older Patients Initiating Dialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1336-1342.	4.5	67
186	Ambulatory Care after Acute Kidney Injury: An Opportunity to Improve Patient Outcomes. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 71.	1.1	67
187	Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. <i>Kidney International</i> , 2005, 68, 2794-2800.	5.2	66
188	The effect of frequent hemodialysis on nutrition and body composition: Frequent Hemodialysis Network Trial. <i>Kidney International</i> , 2012, 82, 90-99.	5.2	65
189	Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium—Phosphate. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 305-312.	4.5	64
190	A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1053-1060.	0.7	64
191	Can Rescaling Dose of Dialysis to Body Surface Area in the HEMO Study Explain the Different Responses to Dose in Women versus Men?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1628-1636.	4.5	63
192	Chronic Kidney Disease in the Urban Poor. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 828-835.	4.5	63
193	Baseline Physical Performance, Health, and Functioning of Participants in the Frequent Hemodialysis Network (FHN) Trial. <i>American Journal of Kidney Diseases</i> , 2011, 57, 101-112.	1.9	63
194	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4834-4844.	3.6	63
195	Higher Serum Creatinine Concentrations in Black Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 992-997.	4.5	62
196	Predialysis Nephrology Care of Older Patients Approaching End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2011, 171, 1371.	3.8	62
197	Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 90-99.	0.7	62
198	A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1332-1338.	4.5	61

#	ARTICLE	IF	CITATIONS
199	Determinants of Cardiac Autonomic Dysfunction in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1821-1827.	4.5	61
200	30-Day Readmissions After an Acute Kidney Injury Hospitalization. <i>American Journal of Medicine</i> , 2017, 130, 163-172.e4.	1.5	61
201	Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. <i>Journal of Human Hypertension</i> , 2014, 28, 18-24.	2.2	59
202	<i>Dialysis Research</i>: Surfaceâ€œAreaâ€œNormalized <i>Kt</i>/<i>V</i>: A Method of Rescaling Dialysis Dose to Body Surface Areaâ€œ”Implications for Differentâ€œSize Patients by Gender. <i>Seminars in Dialysis</i> , 2008, 21, 415-421.	1.3	58
203	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 737-746.	1.7	58
204	Chronic kidney disease care models in low- and middle-income countries: a systematic review. <i>BMJ Global Health</i> , 2018, 3, e000728.	4.7	57
205	Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation. <i>Surgery</i> , 2006, 140, 990-999.	1.9	56
206	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2013, 159, 382.	3.9	56
207	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1619-1628.	27.0	56
208	Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial. <i>Kidney International</i> , 2017, 91, 1186-1192.	5.2	55
209	Incident CKD after Radical or Partial Nephrectomy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 207-216.	6.1	55
210	SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. <i>Annals of Internal Medicine</i> , 2022, 175, 371-378.	3.9	55
211	Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. <i>Critical Care</i> , 2009, 13, 310.	5.8	53
212	Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease. <i>Kidney International</i> , 2015, 88, 178-185.	5.2	53
213	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1495-1504.	6.1	53
214	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	5.2	53
215	Effects of 6-Times-Weekly Versus 3-Times-Weekly Hemodialysis on Depressive Symptoms and Self-reported Mental Health: Frequent Hemodialysis Network (FHN) Trials. <i>American Journal of Kidney Diseases</i> , 2013, 61, 748-758.	1.9	52
216	Home Dialysis in the Prospective Payment System Era. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2993-3004.	6.1	52

#	ARTICLE	IF	CITATIONS
217	Long-Term Safety and Efficacy of a Novel Iron-Containing Phosphate Binder, JTT-751, in Patients Receiving Hemodialysis. , 2014, 24, 261-267.		51
218	Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease. Nephron, 2015, 129, 29-33.	1.8	51
219	Challenging the Validity of the EPO Index. American Journal of Kidney Diseases, 2006, 47, 166.e1-166.e13.	1.9	50
220	Effects of Frequent Hemodialysis on Perceived Caregiver Burden in the Frequent Hemodialysis Network Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 936-942.	4.5	50
221	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. Journal of the American Society of Nephrology: JASN, 2016, 27, 3129-3138.	6.1	50
222	How to Diagnose Solutions to a Quality of Care Problem. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 901-907.	4.5	49
223	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC: Heart Failure, 2021, 9, 807-820.	4.1	49
224	The Comprehensive Dialysis Study (CDS). Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 645-650.	4.5	48
225	Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 261-267.	4.5	48
226	Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2—lessons from evolution, the animal kingdom and rare progeroid syndromes. Nephrology Dialysis Transplantation, 2020, 35, 2036-2045.	0.7	48
227	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrology Dialysis Transplantation, 2022, 37, 1647-1656.	0.7	48
228	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. Journal of the American College of Cardiology, 2013, 61, 1250-1258.	2.8	47
229	Metabolic Profiling of Impaired Cognitive Function in Patients Receiving Dialysis. Journal of the American Society of Nephrology: JASN, 2016, 27, 3780-3787.	6.1	47
230	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care, 2021, 44, 1894-1897.	8.6	47
231	Association of body size with health status in patients beginning dialysis. American Journal of Clinical Nutrition, 2006, 83, 543-549.	4.7	46
232	SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. Journal of the American Society of Nephrology: JASN, 2021, 32, 1575-1581.	6.1	46
233	COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis. Journal of the American Society of Nephrology: JASN, 2022, 33, 33-37.	6.1	46
234	Slowing the Progression of Vascular Calcification in Hemodialysis. Journal of the American Society of Nephrology: JASN, 2003, 14, S310-S314.	6.1	45

#	ARTICLE	IF	CITATIONS
235	Differential Mortality and Transplantation Rates among Asians and Pacific Islanders with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3711-3720.	6.1	45
236	<i>Editorials</i> : Comparison of Proposed Alternative Methods for Rescaling Dialysis Dose: Resting Energy Expenditure, High Metabolic Rate Organ Mass, Liver Size, and Body Surface Area. <i>Seminars in Dialysis</i> , 2008, 21, 377-384.	1.3	45
237	Characteristics of Uninsured Americans with Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2009, 24, 917-922.	2.6	45
238	Risk of Cardiovascular Events after Infection-Related Hospitalizations in Older Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1708-1713.	4.5	45
239	Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. <i>Journal of Human Hypertension</i> , 2011, 25, 98-105.	2.2	45
240	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.	0.7	45
241	Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) Daily Trial. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 168-178.	0.7	45
242	Alport Syndrome Classification and Management. <i>Kidney Medicine</i> , 2020, 2, 639-649.	2.0	45
243	A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1465-1473.	6.1	45
244	Fetuin-A and Change in Body Composition in Older Persons. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4492-4498.	3.6	44
245	Reexploring Differences among For-profit and Nonprofit Dialysis Providers. <i>Health Services Research</i> , 2010, 45, 633-646.	2.0	44
246	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches—Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. <i>American Heart Journal</i> , 2018, 205, 42-52.	2.7	44
247	Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study. <i>PLoS Medicine</i> , 2018, 15, e1002532.	8.4	44
248	Neighborhood Poverty and Kidney Transplantation Among US Asians and Pacific Islanders with End-stage Renal Disease. <i>American Journal of Transplantation</i> , 2008, 8, 2402-2409.	4.7	43
249	Frailty Among Patients Receiving Hemodialysis: Evolution of Components and Associations With Mortality. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 380-386.	3.6	42
250	Race and Mortality after Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2740-2748.	6.1	41
251	Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. <i>Kidney International</i> , 2018, 93, 1475-1482.	5.2	41
252	Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1523-1533.	6.1	41

#	ARTICLE	IF	CITATIONS
253	Cost-Effectiveness of Frequent In-Center Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1792-1797.	6.1	40
254	The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: A systematic review. <i>Hemodialysis International</i> , 2009, 13, 347-359.	0.9	40
255	Outcomes of Infection-Related Hospitalization in Medicare Beneficiaries Receiving In-Center Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2015, 65, 754-762.	1.9	40
256	Associations of Body Mass Index and Body Fat With Markers of Inflammation and Nutrition Among Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2017, 70, 817-825.	1.9	40
257	The Terrible Toll of the Kidney Shortage. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2775-2776.	6.1	40
258	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 24-34.	11.4	40
259	Association of Self-reported Physical Activity With Laboratory Markers of Nutrition and Inflammation: The Comprehensive Dialysis Study. , 2011, 21, 429-437.		39
260	Validation of Reported Predialysis Nephrology Care of Older Patients Initiating Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1078-1085.	6.1	39
261	High prevalence of type 2 diabetes among the urban middle class in Bangladesh. <i>BMC Public Health</i> , 2013, 13, 1032.	2.9	39
262	Risk Factors for Infection-Related Hospitalization in In-Center Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2170-2180.	4.5	39
263	Prehabilitation for kidney transplant candidates: Is it time?. <i>Clinical Transplantation</i> , 2017, 31, e13020.	1.6	39
264	Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1916-1923.	0.7	38
265	Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 802-810.	0.7	38
266	Physical and sexual function in women with chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 868-876.	1.9	37
267	The Effect of Increased Frequency of Hemodialysis on Volume-Related Outcomes: A Secondary Analysis of the Frequent Hemodialysis Network Trials. <i>Blood Purification</i> , 2016, 41, 277-286.	1.8	37
268	Bioelectrical Impedance Analysis Measures and Clinical Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 662-672.	1.9	37
269	Hypertension Hot Potato – Anatomy of the Angiotensin-Receptor Blocker Recalls. <i>New England Journal of Medicine</i> , 2019, 380, 1589-1591.	27.0	37
270	Optimal Initiation and Management of Dialysis Therapy. <i>Operations Research</i> , 2008, 56, 1428-1449.	1.9	36



#	ARTICLE	IF	CITATIONS
271	Baseline Characteristics of Participants in the Frequent Hemodialysis Network (FHN) Daily and Nocturnal Trials. <i>American Journal of Kidney Diseases</i> , 2011, 57, 90-100.	1.9	36
272	Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1115-1124.	0.7	36
273	Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 46-54.	4.4	36
274	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.	0.8	36
275	Coronary and aortic calcifications in patients new to dialysis. <i>Hemodialysis International</i> , 2004, 8, 265-272.	0.9	35
276	Improving Care after Acute Kidney Injury: A Prospective Time Series Study. <i>Nephron</i> , 2015, 131, 43-50.	1.8	35
277	Perioperative THR-184 and AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 670-679.	6.1	35
278	Ferumoxytol for the treatment of iron deficiency anemia. <i>Expert Review of Hematology</i> , 2018, 11, 829-834.	2.2	35
279	Dialysis versus Medical Management at Different Ages and Levels of Kidney Function in Veterans with Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2169-2177.	6.1	34
280	Variation in Nephrologist Visits to Patients on Hemodialysis across Dialysis Facilities and Geographic Locations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 987-994.	4.5	33
281	How to Measure and Interpret Quality Improvement Data. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 908-914.	4.5	33
282	Longitudinal Measures of Serum Albumin and Prealbumin Concentrations in Incident Dialysis Patients: The Comprehensive Dialysis Study. , 2013, 23, 91-97.		32
283	Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States. , 2008, 18, 323-331.		31
284	Comparison of Hospitalization Rates among For-Profit and Nonprofit Dialysis Facilities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 73-81.	4.5	31
285	Antihypertensive medications and sexual function in women. <i>Journal of Hypertension</i> , 2016, 34, 1224-1231.	0.5	31
286	The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1878-1884.	8.6	31
287	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. <i>American Journal of Nephrology</i> , 2021, 52, 180-189.	3.1	31
288	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 753-766.	2.9	31

#	ARTICLE	IF	CITATIONS
289	Kidney Function as a Predictor of Loss of Lean Mass in Older Adults: Health, Aging and Body Composition Study. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1578-1584.	2.6	30
290	Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. <i>Hemodialysis International</i> , 2017, 21, 190-196.	0.9	30
291	Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 346-353.	6.1	29
292	Reasons for non-enrollment in a cohort study of ARF: the Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. <i>American Journal of Kidney Diseases</i> , 2003, 42, 507-512.	1.9	28
293	Medication errors in chronic kidney disease: one piece in the patient safety puzzle. <i>Kidney International</i> , 2009, 76, 1123-1125.	5.2	28
294	Homelessness and CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1094-1102.	4.5	28
295	HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes. <i>Scientific Reports</i> , 2017, 7, 43728.	3.3	28
296	Paying for Hemodialysis in Kerala, India: A Description of Household Financial Hardship in the Context of Medical Subsidy. <i>Kidney International Reports</i> , 2019, 4, 390-398.	0.8	28
297	Relative sarcopenia and mortality and the modifying effects of chronic kidney disease and adiposity. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 338-346.	7.3	28
298	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 339-346.	0.7	28
299	National Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1454-1463.	6.1	28
300	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	6.3	28
301	Studying the Prevention of Acute Kidney Injury: Lessons from an 18th-Century Mathematician: Table 1.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1124-1127.	4.5	27
302	Lessons for Successful Study Enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 955-961.	4.5	27
303	Is there "Cherry Picking" in the ESRD Program? Perceptions from a Dialysis Provider Survey. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 772-777.	4.5	27
304	Bardoxolone Methyl in Type 2 Diabetes and Advanced Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1767-1769.	27.0	27
305	Can twice weekly hemodialysis expand patient access under resource constraints?. <i>Hemodialysis International</i> , 2017, 21, 445-452.	0.9	27
306	Prospective Biopsy-Based Study of CKD of Unknown Etiology in Sri Lanka. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 224-232.	4.5	27

#	ARTICLE	IF	CITATIONS
307	Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2303-2314.	6.1	27
308	Hyperparathyroidism and dialysis vintage. <i>Clinical Nephrology</i> , 2000, 54, 295-300.	0.7	27
309	Beyond Framingham: Cardiovascular Risk Profiling in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1539-1541.	6.1	26
310	Utility in Treating Kidney Failure in End-Stage Liver Disease With Simultaneous Liver-Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1111-1119.	1.0	26
311	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019, 96, 1030-1036.	5.2	26
312	Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones. <i>JAMA Surgery</i> , 2020, 155, 861.	4.3	26
313	Validating Appetite Assessment Tools Among Patients Receiving Hemodialysis. , 2016, 26, 103-110.		25
314	Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?. <i>Urology</i> , 2017, 100, 65-71.	1.0	25
315	Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. <i>American Journal of Hypertension</i> , 2018, 31, 97-107.	2.0	25
316	Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107402.	2.3	25
317	One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1769-1778.	0.7	25
318	Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?. <i>European Urology</i> , 2016, 70, 227-230.	1.9	24
319	Receipt of Nephrology Care and Clinical Outcomes Among Veterans With Advanced CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 705-714.	1.9	24
320	Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System. <i>JAMA Internal Medicine</i> , 2018, 178, 1358.	5.1	24
321	Evolving Practices in Critical Care and Potential Implications for Management of Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 869-873.	4.5	23
322	Unplanned Emergency Department Visits and Hospital Admissions Following Ureteroscopy: Do Ureteral Stents Make a Difference?. <i>Urology</i> , 2018, 117, 44-49.	1.0	23
323	Toward the Optimal dose Metric in Continuous Renal Replacement Therapy. <i>International Journal of Artificial Organs</i> , 2012, 35, 413-424.	1.4	22
324	Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. <i>Hemodialysis International</i> , 2012, 16, 188-197.	0.9	22

#	ARTICLE	IF	CITATIONS
325	Declining Rates of Inpatient Parathyroidectomy for Primary Hyperparathyroidism in the US. PLoS ONE, 2016, 11, e0161192.	2.5	22
326	Hemodialysis Hospitalizations and Readmissions: The Effects of Payment Reform. American Journal of Kidney Diseases, 2017, 69, 237-246.	1.9	22
327	Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS ONE, 2017, 12, e0188712.	2.5	22
328	Payer Type, Race/Ethnicity, and the Timing of Surgical Management of Urinary Stone Disease. Journal of Endourology, 2019, 33, 152-158.	2.1	22
329	Challenges to enrollment and randomization of the frequent hemodialysis network (FHN) daily trial. Journal of Nephrology, 2012, 25, 302-309.	2.0	22
330	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. Nephrology Dialysis Transplantation, 2013, 28, 2841-2850.	0.7	21
331	The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. Contemporary Clinical Trials, 2016, 48, 119-124.	1.8	21
332	Managing Hypertension in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 40-43.	6.1	21
333	Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1128-1138.	4.5	21
334	Prevalence of chronic kidney disease and risk factors for its progression: A cross-sectional comparison of Indians living in Indian versus U.S. cities. PLoS ONE, 2017, 12, e0173554.	2.5	21
335	Removing Disincentives to Kidney Donation: A Quantitative Analysis. Journal of the American Society of Nephrology: JASN, 2019, 30, 1349-1357.	6.1	21
336	Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis. Annals of Internal Medicine, 2021, 174, 1073-1080.	3.9	21
337	Chronic Kidney Disease Mineral Bone Disorder and Health-Related Quality of Life Among Incident End-Stage Renal-Disease Patients. , 2007, 17, 305-313.		20
338	A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology. Hemodialysis International, 2009, 13, 360-362.	0.9	20
339	Prognostic Stratification in Older Adults Commencing Dialysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 1033-1039.	3.6	20
340	Characteristics and Performance of Minority-Serving Dialysis Facilities. Health Services Research, 2014, 49, 971-991.	2.0	20
341	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 539-546.	4.5	20
342	Consolidation in the Dialysis Industry, Patient Choice, and Local Market Competition. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 536-545.	4.5	20

#	ARTICLE	IF	CITATIONS
343	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. CKJ: Clinical Kidney Journal, 2020, 13, 75-84.	2.9	20
344	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation, 2021, 36, 2039-2048.	0.7	20
345	“Wishing Don’t Make it So” Why We Need a Randomized Clinical Trial of High-Intensity Hemodialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 2850-2853.	6.1	20
346	Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. , 2002, 12, 170-176.		19
347	A Simulation Model to Estimate the Cost and Effectiveness of Alternative Dialysis Initiation Strategies. Medical Decision Making, 2006, 26, 535-549.	2.4	19
348	Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study. American Journal of Kidney Diseases, 2015, 66, 106-113.	1.9	19
349	Analyzing Health-Related Quality of Life in the EVOLVE Trial. Medical Decision Making, 2016, 36, 965-972.	2.4	19
350	Cinacalcet, dialysate calcium concentration, and cardiovascular events in the <scp>EVOLVE</scp> trial. Hemodialysis International, 2016, 20, 421-431.	0.9	19
351	Effectiveness of Quality Improvement Strategies for the Management of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1601-1614.	4.5	19
352	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	1.9	18
353	Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD. Clinical and Translational Science, 2021, 14, 299-309.	3.1	18
354	Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology, 2005, 25, 393-399.	3.1	17
355	Dialysis session length (â€œtâ€œ) as a determinant of the adequacy of dialysis. Seminars in Nephrology, 2005, 25, 90-95.	1.6	17
356	Assessing the treatment effect in a randomized controlled trial with extensive nonâ€œadherence: the EVOLVE trial. Pharmaceutical Statistics, 2015, 14, 242-251.	1.3	17
357	Provider Visits and Early Vascular Access Placement in Maintenance Hemodialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1990-1997.	6.1	17
358	Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension, 2016, 67, 550-555.	2.7	17
359	Physical Performance Testing in Kidney Transplant Candidates at the Top of the Waitlist. American Journal of Kidney Diseases, 2020, 76, 815-825.	1.9	17
360	In critically ill patients with acute renal failure, outcomes, not dollars, should drive modality choice *. Critical Care Medicine, 2003, 31, 644-646.	0.9	17

#	ARTICLE	IF	CITATIONS
361	Effects of physician payment reform on provision of home dialysis. American Journal of Managed Care, 2016, 22, e215-23.	1.1	17
362	Cinacalcet for Cardiovascular Disease in Patients Undergoing Dialysis. New England Journal of Medicine, 2013, 368, 1842-1845.	27.0	16
363	Anticoagulation, delivered dose and outcomes in <scp>CRRT</scp>: The program to improve care in acute renal disease (<scp>PICARD</scp>). Hemodialysis International, 2014, 18, 641-649.	0.9	16
364	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in Health, 2015, 18, 1079-1087.	0.3	16
365	The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials. Nephrology Dialysis Transplantation, 2016, 31, 984-991.	0.7	16
366	Market Competition and Health Outcomes in Hemodialysis. Health Services Research, 2018, 53, 3680-3703.	2.0	16
367	SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1036-1038.	4.5	16
368	Tesio Catheter Access for Long-term Maintenance Hemodialysis. Radiology, 2006, 241, 284-290.	7.3	15
369	The 2011 ESRD Prospective Payment System: An Uncontrolled Experiment. American Journal of Kidney Diseases, 2011, 57, 542-546.	1.9	15
370	Modeled Urea Distribution Volume and Mortality in the HEMO Study. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1129-1138.	4.5	15
371	Piecewise Analysis of Patient Survival after Onset of AKI. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1679-1684.	4.5	15
372	Estimation of 24-Hour Urine Phosphate Excretion From Spot Urine Collection: Development of a Predictive Equation. , 2014, 24, 194-199.		15
373	Central venous pressure and the risk of diuretic-associated acute kidney injury in patients after cardiac surgery. American Heart Journal, 2020, 221, 67-73.	2.7	15
374	Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. Mayo Clinic Proceedings, 2021, 96, 2114-2122.	3.0	15
375	Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. Journal of General Internal Medicine, 2022, 37, 3380-3387.	2.6	15
376	Calcification or Classification?. Journal of the American Society of Nephrology: JASN, 2005, 16, 293-295.	6.1	14
377	On the relative safety of intravenous iron formulations: New answers, new questions. American Journal of Hematology, 2010, 85, 643-644.	4.1	14
378	Declining Rates of Hip Fracture in End-Stage Renal Disease: Analysis From the 2003â€“2011 Nationwide Inpatient Sample. Journal of Bone and Mineral Research, 2017, 32, 2297-2303.	2.8	14

#	ARTICLE	IF	CITATIONS
379	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1816-1824.	4.5	14
380	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	2.5	14
381	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1113-1117.	2.3	14
382	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1447-1455.	1.7	14
383	The Decline in Residual Renal Function in Hemodialysis Is Slow and Age Dependent. <i>Hemodialysis International</i> , 2003, 7, 17-22.	0.9	13
384	Medicare ESRD Prospective Payment System: Weighing the Evidence. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1164-1165.	6.1	13
385	Evaluating Risk of ESRD in the Urban Poor. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1434-1442.	6.1	13
386	Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. <i>American Journal of Nephrology</i> , 2016, 44, 130-140.	3.1	13
387	The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. <i>Journal of Human Hypertension</i> , 2016, 30, 204-209.	2.2	13
388	Thyroid function in end stage renal disease and effects of frequent hemodialysis. <i>Hemodialysis International</i> , 2017, 21, 534-541.	0.9	13
389	Mandating Staffing Ratios in Hemodialysis Facilities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1110-1112.	4.5	13
390	Association of Hospitalization and Mortality Among Patients Initiating Dialysis With Hemodialysis Facility Ownership and Acquisitions. <i>JAMA Network Open</i> , 2019, 2, e193987.	5.9	13
391	Intradialytic Symptoms and Recovery Time in Patients on Thrice-Weekly In-Center Hemodialysis: A Cross-sectional Online Survey. <i>Kidney Medicine</i> , 2020, 2, 125-130.	2.0	13
392	Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver& kidney Transplant as a Case Example. <i>Transplantation</i> , 2020, 104, 387-394.	1.0	13
393	AKI&A Relevant Safety End Point?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 508-512.	1.9	13
394	The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 136-144.	2.9	13
395	Effect of a Home-Based Exercise Program on Indices of Physical Function and Quality of Life in Elderly Maintenance Hemodialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 196-206.	2.0	13
396	The &quot;Advancing American Kidney Health&quot; Executive Order: Challenges and Opportunities for the Large Dialysis Organizations. <i>American Journal of Kidney Diseases</i> , 2020, 76, 731-734.	1.9	13

#	ARTICLE	IF	CITATIONS
397	Cost-effectiveness of cancer screening in end-stage renal disease. Archives of Internal Medicine, 1996, 156, 1345-50.	3.8	13
398	Assessing the Nutritional Status of Patients with End-Stage Renal Disease. Seminars in Dialysis, 1997, 10, 108-114.	1.3	12
399	Increased fluid intake does not augment capacity to lay down new collagen in nursing home residents at risk for pressure ulcers: A randomized, controlled clinical trial. Wound Repair and Regeneration, 2009, 17, 780-788.	3.0	12
400	Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis. Forum for Health Economics and Policy, 2014, 17, 53-77.	0.8	12
401	Provider Visit Frequency and Vascular Access Interventions in Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 269-277.	4.5	12
402	Association of bioimpedance spectroscopy-based volume estimation with postdialysis hypotension in patients receiving hemodialysis. Hemodialysis International, 2015, 19, 536-542.	0.9	12
403	Understanding barriers to home-based and self-care in-center hemodialysis. Hemodialysis International, 2016, 20, 235-241.	0.9	12
404	Results of human factors testing in a novel Hemodialysis system designed for ease of patient use. Hemodialysis International, 2016, 20, 643-649.	0.9	12
405	Early to Dialyze. JAMA - Journal of the American Medical Association, 2016, 315, 2171.	7.4	12
406	Acute Kidney Injury Due to Diarrheal Illness Requiring Hospitalization: Data from the National Inpatient Sample. Journal of General Internal Medicine, 2018, 33, 1520-1527.	2.6	12
407	Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney International Reports, 2019, 4, 987-994.	0.8	12
408	Current Status of Angiotensin Receptor Blocker Recalls. Hypertension, 2019, 74, 1275-1278.	2.7	12
409	Chronic Kidney Disease and the Adiposity Paradox: Valid or Confounded?. , 2019, 29, 521-528.		12
410	An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS ONE, 2019, 14, e0213774.	2.5	12
411	Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease-Related Medications in Veterans. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1773-1780.	4.5	12
412	Prior Hospitalization Burden and the Relatedness of 30-Day Readmissions in Patients Receiving Hemodialysis. Journal of the American Society of Nephrology: JASN, 2019, 30, 323-335.	6.1	12
413	Targeting Sedentary Behavior in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 717-726.	4.5	12
414	Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2116572.	5.9	12



#	ARTICLE	IF	CITATIONS
415	Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). <i>Kidney360</i> , 2021, 2, 1600-1610.	2.1	12
416	Urinary Stone Disease in Pregnancy: A Claims Based Analysis of 1.4 Million Patients. <i>Journal of Urology</i> , 2020, 203, 957-961.	0.4	12
417	Emerging Role of Clinical Genetics in CKD. <i>Kidney Medicine</i> , 2022, 4, 100435.	2.0	12
418	Regional Variation in Kidney Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 152-159.	4.5	11
419	Calibration of the Brief Food Frequency Questionnaire Among Patients on Dialysis. , 2014, 24, 151-156.e1.		11
420	Donation, Not Disease! A Multiple-Hit Hypothesis on Development of Post-Donation Kidney Disease. <i>Current Transplantation Reports</i> , 2017, 4, 320-326.	2.0	11
421	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. <i>BMJ Global Health</i> , 2017, 2, e000453.	4.7	11
422	Would government compensation of living kidney donors exploit the poor? An empirical analysis. <i>PLoS ONE</i> , 2018, 13, e0205655.	2.5	11
423	Outcomes after left ventricular assist device implantation in patients with acute kidney injury. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 477-486.e3.	0.8	11
424	Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis – Subgroup Analyses of the CALIPSO Trial. <i>Kidney International Reports</i> , 2020, 5, 2178-2182.	0.8	11
425	Osteoporosis, Fractures, and Bone Mineral Density Screening in Veterans With Kidney Stone Disease. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 872-878.	2.8	11
426	Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 736-745.	4.5	11
427	Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017. <i>JAMA Network Open</i> , 2022, 5, e221847.	5.9	11
428	Toward the Promise of Renal Replacement Therapy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 839-840.	6.1	10
429	Thienopyridine Use After Coronary Stenting in Low Income Patients Enrolled in Medicare Part D Receiving Maintenance Dialysis. <i>Journal of the American Heart Association</i> , 2014, 3, e001356.	3.7	10
430	Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 430-437.	0.7	10
431	Predialysis volume overload and patient-reported sleep duration and quality in patients receiving hemodialysis. <i>Hemodialysis International</i> , 2017, 21, 133-141.	0.9	10
432	Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 693-707.	1.4	10

#	ARTICLE	IF	CITATIONS
433	Percutaneous Kidney Biopsy and the Utilization of Blood Transfusion and Renal Angiography Among Hospitalized Adults. <i>Kidney International Reports</i> , 2019, 4, 1435-1445.	0.8	10
434	Safety and efficacy of the Tablo hemodialysis system for in-center and home hemodialysis. <i>Hemodialysis International</i> , 2020, 24, 22-28.	0.9	10
435	Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 232-240.	2.1	9
436	Misclassification of Obesity by Body Mass Index Among Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2016, 67, 709-711.	1.9	9
437	Infrequent Provision of Palliative Care to Patients with Dialysis-Requiring AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1744-1752.	4.5	9
438	Comparing Simultaneous Liver-Kidney Transplant Strategies. <i>Transplantation</i> , 2018, 102, e219-e228.	1.0	9
439	Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis. <i>American Journal of Nephrology</i> , 2019, 49, 125-132.	3.1	9
440	Early Delays in Insurance Coverage and Long-term Use of Home-based Peritoneal Dialysis. <i>Medical Care</i> , 2020, 58, 632-642.	2.4	9
441	Toward telemedicine-compatible physical functioning assessments in kidney transplant candidates. <i>Clinical Transplantation</i> , 2021, 35, e14173.	1.6	9
442	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	2.7	9
443	Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. , 2022, 32, e1-e14.		9
444	Patient and Provider Characteristics Associated With Sodium-Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease. <i>Clinical Diabetes</i> , 2020, 38, 240-247.	2.2	9
445	The Urine Albumin-to-Creatinine Ratio and Kidney Function after Nephrectomy. <i>Journal of Urology</i> , 2020, 204, 231-238.	0.4	9
446	SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients. <i>Kidney360</i> , 2022, 3, 10.34067/KID.0005732021.	2.1	9
447	Sex differences in obesity, dietary habits, and physical activity among urban middle-class Bangladeshis. <i>International Journal of Health Sciences</i> , 2016, 10, 363-72.	0.4	9
448	The tortoise and hare on hemodialysis: Does slow and steady win the race?. <i>Kidney International</i> , 2006, 70, 24-25.	5.2	8
449	Associations of lipoproteins with cardiovascular and infection-related outcomes in patients receiving hemodialysis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 481-487.e14.	1.5	8
450	Use of Estimating Equations for Dosing Antimicrobials in Patients with Acute Kidney Injury Not Receiving Renal Replacement Therapy. <i>Journal of Clinical Medicine</i> , 2018, 7, 211.	2.4	8

#	ARTICLE	IF	CITATIONS
451	Prevalence of twenty-four hour urine testing in Veterans with urinary stone disease. PLoS ONE, 2019, 14, e0220768.	2.5	8
452	Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. CKJ: Clinical Kidney Journal, 2021, 14, 366-374.	2.9	8
453	Removing Race from eGFR calculations: Implications for Urologic Care. Urology, 2022, 162, 42-48.	1.0	8
454	Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis. Value in Health, 2021, 24, 1592-1602.	0.3	8
455	Modification of eGFR-Based CKD Definitions: Perfect, or Enemy of the Good?. Journal of the American Society of Nephrology: JASN, 2019, 30, 1807-1809.	6.1	8
456	Performance characteristics of a dialysis-related amyloidosis questionnaire.. Journal of the American Society of Nephrology: JASN, 1996, 7, 1235-1240.	6.1	8
457	QuÃ©let (body mass) index and effects of dapagliflozin in chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 827-837.	4.4	8
458	Gridlock on the Road to Kidney Transplantation. American Journal of Kidney Diseases, 2001, 37, 435-437.	1.9	7
459	Intensity of Dialysis in Established Acute Renal Failure. Seminars in Dialysis, 1996, 9, 476-480.	1.3	7
460	<i>Insight</i>: Effects of Reduced Intradialytic Urea Generation Rate and Residual Renal Clearance on Modeled Urea Distribution Volume and <i>Kt/V</i> in Conventional, Daily, and Nocturnal Dialysis. Seminars in Dialysis, 2010, 23, 19-24.	1.3	7
461	Risk prediction to inform surveillance of chronic kidney disease in the US Healthcare Safety Net: a cohort study. BMC Nephrology, 2016, 17, 57.	1.8	7
462	Market Consolidation and Mortality in Patients Initiating Hemodialysis. Value in Health, 2019, 22, 69-76.	0.3	7
463	Effect of Intensive vs Standard Blood Pressure Treatment Upon Erectile Function in Hypertensive Men: Findings From the Systolic Blood Pressure Intervention Trial. Journal of Sexual Medicine, 2020, 17, 238-248.	0.6	7
464	Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. American Journal of Physiology - Renal Physiology, 2021, 320, F133-F144.	2.7	7
465	Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension. American Journal of Physiology - Renal Physiology, 2021, 320, F325-F335.	2.7	7
466	SNF472: mechanism of action and results from clinical trials. Current Opinion in Nephrology and Hypertension, 2021, 30, 424-429.	2.0	7
467	Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. Kidney360, 2020, 1, 368-375.	2.1	7
468	Dialysis: Cost-effective â€œSUPPORTâ€•for patients with acute renal failure. American Journal of Kidney Diseases, 1998, 31, 545-549.	1.9	6

#	ARTICLE	IF	CITATIONS
469	Renal insufficiency with monoclonal gammopathy and urticarial vasculitis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 203-207.	1.9	6
470	Hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary?. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 366-371.	2.9	6
471	Navigating Toward Research Success in Times of Uncertainty: Funding Opportunities for Early Career Investigators in Nephrology. <i>American Journal of Kidney Diseases</i> , 2015, 65, 381-383.	1.9	6
472	How to Use Quality Improvement Tools in Clinical Practice: A Primer for Nephrologists. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 891-892.	4.5	6
473	Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia. <i>American Journal of Hematology</i> , 2018, 93, E154-E156.	4.1	6
474	Acute Kidney Injury in Children Hospitalized With Diarrheal Illness in the United States. <i>Hospital Pediatrics</i> , 2019, 9, 933-941.	1.3	6
475	Laboratory-wide association study of survival with prostate cancer. <i>Cancer</i> , 2021, 127, 1102-1113.	4.1	6
476	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. <i>BMC Nephrology</i> , 2021, 22, 69.	1.8	6
477	Body Composition Changes Following Dialysis Initiation and Cardiovascular and Mortality Outcomes in CRIC (Chronic Renal Insufficiency Cohort): A Bioimpedance Analysis Substudy. <i>Kidney Medicine</i> , 2021, 3, 327-334.e1.	2.0	6
478	Karnofsky Performance Score "Failure to Thrive as a Frailty Proxy?. <i>Transplantation Direct</i> , 2021, 7, e708.	1.6	6
479	Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. <i>Urology</i> , 2021, 155, 70-76.	1.0	6
480	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. <i>Kidney International Reports</i> , 2022, 7, 699-707.	0.8	6
481	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. <i>Journal of the American Heart Association</i> , 2022, 11, e022003.	3.7	6
482	Current and Future Therapies for the Medical Management of Secondary Hyperparathyroidism. <i>Seminars in Dialysis</i> , 1998, 11, 267-270.	1.3	5
483	Chronic Kidney Disease and Cardiovascular Therapeutics. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1162-1164.	2.8	5
484	World Kidney Day 2011. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 397-398.	6.1	5
485	Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 654-662.	1.9	5
486	Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?. <i>Kidney International</i> , 2016, 90, 460-462.	5.2	5

#	ARTICLE	IF	CITATIONS
487	Re-evaluation of re-hospitalization and rehabilitation in renal research. <i>Hemodialysis International</i> , 2017, 21, 422-429.	0.9	5
488	Benefits and risks of intensive blood pressure lowering in advanced chronic kidney disease. <i>Journal of Internal Medicine</i> , 2018, 284, 106-107.	6.0	5
489	Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 34, 1924-1931.	0.7	5
490	Safety-Net Care for Maintenance Dialysis in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 424-433.	6.1	5
491	Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 616-623.	0.7	5
492	Innovation in hemodialysis: Using the Biodesign process to identify unmet needs. <i>Journal of Vascular Access</i> , 2021, 22, 509-514.	0.9	5
493	Prolonged Hospitalization Following Acute Respiratory Failure. <i>Chest</i> , 2021, 159, 1867-1874.	0.8	5
494	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. <i>Kidney International Reports</i> , 2021, 6, 1513-1524.	0.8	5
495	Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 441-442.	0.4	4
496	Urine Electrolyte Composition and Diuretic Therapy in Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 697-698.	3.9	4
497	ISCHEMIA in chronic kidney disease: improving the representation of patients with chronic kidney disease in cardiovascular trials. <i>Kidney International</i> , 2016, 89, 1178-1179.	5.2	4
498	Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2132.	7.4	4
499	Exploring Care Attributes of Nephrologists Ranking Favorably on Measures of Value. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2464-2472.	6.1	4
500	Estimated Effects of Early Diuretic Use in Critical Illness. , 2019, 1, e0021.		4
501	Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Hypertension</i> , 2020, 76, 1725-1733.	2.7	4
502	The organ procurement costs of expanding deceased donor organ acceptance criteria: Evidence from a cost function model. <i>American Journal of Transplantation</i> , 2021, 21, 3694-3703.	4.7	4
503	Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis: A Cluster Randomized Trial. <i>Kidney360</i> , 2021, 2, 1752-1760.	2.1	4
504	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. <i>American Journal of Kidney Diseases</i> , 2020, 76, 842-850.	1.9	4

#	ARTICLE	IF	CITATIONS
505	Twenty-four-hour Urine Testing and Urinary Stone Disease Recurrence in Veterans. <i>Urology</i> , 2022, 159, 33-40.	1.0	4
506	Non-immunologic predictors of chronic renal allograft failure: data from the United Network of Organ Sharing. <i>Kidney International, Supplement</i> , 1995, 52, S48-51.	0.1	4
507	Issues in Evaluating the Cost-Effectiveness of Dialysis. <i>Seminars in Dialysis</i> , 1999, 12, 355-358.	1.3	3
508	A 43-Year-Old Woman With Chronic Renal Insufficiency. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1252.	7.4	3
509	Screening to prevent coronary events or screening to detect obstruction?. <i>American Journal of Kidney Diseases</i> , 2004, 43, 940.	1.9	3
510	Kidney Disease, Hospitalized Hypertension, and Cardiovascular Events: Cause or Consequence?. <i>Circulation</i> , 2010, 121, 2160-2161.	1.6	3
511	Aspirin and Arteriovenous Graft Thrombosis in Hemodialysis: Just What the Doctor Ordered?. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 595-597.	6.1	3
512	Cardiovascular and Renal Outcomes Trials-Is There a Difference?. <i>American Journal of Cardiology</i> , 2015, 116, 982-988.	1.6	3
513	SO030 ONE YEAR EFFICACY AND SAFETY OF INTRAVENOUS (IV) ETELCALCETIDE (AMG 416) IN PATIENTS ON HEMODIALYSIS (HD) WITH SECONDARY HYPERPARATHYROIDISM (SHPT). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i13-i14.	0.7	3
514	Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. <i>Drugs in R and D</i> , 2017, 17, 159-166.	2.2	3
515	Updated guidelines for the diagnosis and management of high blood pressure: implications for clinical practice in nephrology. <i>Kidney International</i> , 2018, 93, 768-770.	5.2	3
516	Antihypertensive medication withholding practices in hemodialysis: A survey study of patients and providers. <i>Hemodialysis International</i> , 2018, 22, 415-418.	0.9	3
517	Differential Molecular Modeling Predictions of Mid and Conventional Dialysate Flows. <i>Blood Purification</i> , 2019, 47, 369-376.	1.8	3
518	Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. <i>Hemodialysis International</i> , 2021, 25, 78-85.	0.9	3
519	Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?. <i>American Journal of Kidney Diseases</i> , 2021, 77, 478-480.	1.9	3
520	And Then There Were Three: Effects of Pretransplant Dialysis on Multiorgan Transplantation. <i>Transplantation Direct</i> , 2021, 7, e657.	1.6	3
521	Cost Structures of US Organ Procurement Organizations. <i>Transplantation</i> , 2021, 105, 2612-2619.	1.0	3
522	Estimated impact of novel coronavirus-19 and transplant center inactivity on end-stage renal disease-related patient mortality in the United States. <i>Clinical Transplantation</i> , 2021, 35, e14292.	1.6	3

#	ARTICLE	IF	CITATIONS
523	Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e23-12.e30.	1.6	3
524	Association of 152 Biomarker Reference Intervals with All-Cause Mortality in Participants of a General United States Survey from 1999 to 2010. Clinical Chemistry, 2021, 67, 500-507.	3.2	3
525	Population-based identification and temporal trend of children with primary nephrotic syndrome: The Kaiser Permanente nephrotic syndrome study. PLoS ONE, 2021, 16, e0257674.	2.5	3
526	Breaking the Barriers to Innovation in Kidney Care. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 591-593.	4.5	3
527	Oh! What a Tangled Web We Weave. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1066-1067.	4.5	2
528	FP152EFFECT OF BARDOXOLONE METHYL TREATMENT ON URINARY ALBUMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE - POST-HOC ANALYSIS FROM BEAM AND BEACON. Nephrology Dialysis Transplantation, 2018, 33, i27-i27.	0.7	2
529	Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?. Journal of Clinical Hypertension, 2018, 20, 1644-1645.	2.0	2
530	SP104DECREASES IN WEIGHT WITH BARDOXOLONE METHYL IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. Nephrology Dialysis Transplantation, 2018, 33, i379-i379.	0.7	2
531	FO022BARDOXOLONE METHYL PREVENTS EGFR DECLINE IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. Nephrology Dialysis Transplantation, 2018, 33, i10-i10.	0.7	2
532	Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. American Journal of Hypertension, 2019, 32, 1170-1177.	2.0	2
533	Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 107423.	2.3	2
534	Treatment of metabolic acidosis with an intestinal binder. Lancet, The, 2019, 393, 1387-1388.	13.7	2
535	Correlates and Consequences of High Serum Irisin Concentration in Patients on Hemodialysis: A Longitudinal Analysis. , 2020, 31, 389-396.		2
536	Patient-reported outcomes from the investigational device exemption study of the Tablo hemodialysis system. Hemodialysis International, 2020, 24, 480-486.	0.9	2
537	Reducing the Shortage of Transplant Kidneys: A Lost Opportunity for the US Health Resources and Services Administration (HRSA). American Journal of Kidney Diseases, 2021, 77, 963-966.	1.9	2
538	Characteristics and Performance of Minority-Serving Dialysis Facilities. , 2014, 49, 971.		2
539	The Predialysis Serum Sodium Level Modifies the Effect of Hemodialysis Frequency on Left-Ventricular Mass: The Frequent Hemodialysis Network Trials. Kidney and Blood Pressure Research, 2021, 46, 768-776.	2.0	2
540	Updates in Management and Timing of Dialysis in Acute Kidney Injury. Journal of Hospital Medicine, 2019, 14, 232.	1.4	2

#	ARTICLE	IF	CITATIONS
541	Dysgeusia and Dysosmia in Chronic Kidney Disease: NHANES 2011-2014. , 2022, 32, 537-541.		2
542	Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. European Urology Open Science, 2022, 35, 29-36.	0.4	2
543	Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter <sup>2</sup> inhibitors versus dipeptidyl peptidase <sup>4</sup> inhibitors in patients with diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 928-937.	4.4	2
544	Changing the Trajectory of Heart Failure and Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, , CJN.00470122.	4.5	2
545	Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. JAMA Cardiology, 2022, 7, 825.	6.1	2
546	Phosphorus binders and survival: need for randomized trials. Nature Reviews Nephrology, 2009, 5, 368-370.	9.6	1
547	Off-Label Use of Phosphate Binders in Non-Dialysis-Dependent CKD. American Journal of Kidney Diseases, 2010, 56, 813-816.	1.9	1
548	GFR estimating equations, CKD prevalence and the public health. Journal of Internal Medicine, 2010, 267, 354-356.	6.0	1
549	Venous Thromboembolism. Circulation, 2012, 126, 1937-1938.	1.6	1
550	Lowering Blood Pressure to Lower the Risk of Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2014, 63, 900-902.	1.9	1
551	Dialysis Plus Do Not Resuscitate" Not a Contradiction. JAMA Internal Medicine, 2015, 175, 1035.	5.1	1
552	Preparing for Hemodialysis. , 2020, , 1157-1173.		1
553	A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. Journal of Vascular Access, 2020, 21, 467-474.	0.9	1
554	Performance versus Risk Factor-Based Approaches to Coronary Artery Disease Screening in Waitlisted Kidney Transplant Candidates. CardioRenal Medicine, 2021, 11, 140-150.	1.9	1
555	Laboratory correlates of SARS-CoV-2 seropositivity in a nationwide sample of patients on dialysis in the U.S.. PLoS ONE, 2021, 16, e0249466.	2.5	1
556	Asymmetric dimethylarginine, erythropoietin resistance, and anemia in CKD. Annals of Translational Medicine, 2019, 7, S86-S86.	1.7	1
557	The ongoing search for a robust clinical prediction model of ICU AKI. Clinical Nephrology, 2020, 93, 160-162.	0.7	1
558	Trends in Coronary Artery Disease Screening before Kidney Transplantation. Kidney360, 2022, 3, 516-523.	2.1	1



#	ARTICLE	IF	CITATIONS
559	Assessment and management of vascular disease risk in patients with chronic kidney disease. <i>Journal of Clinical Lipidology</i> , 2011, 5, 251-260.	1.5	0
560	66 DIABETIC SEVERITY AND RISK OF KIDNEY STONE DISEASE. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
561	Reply. <i>Urology</i> , 2014, 83, 779-780.	1.0	0
562	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2014, 160, 143.	3.9	0
563	Reforming Medicare's Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism. <i>Health Services Research</i> , 2014, 49, n/a-n/a.	2.0	0
564	Planning for Hemodialysis. , 2015, , 751-764.		0
565	A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia" <i>American Journal of Hematology</i> , 2018, 93, E232-E233.	4.1	0
566	Challenges in Assessing the Burden of Hospitalized Heart Failure in End-Stage Kidney Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 534-536.	1.7	0
567	Toward Greater Scrutiny of Dialysate Flow: Reply to the Letter to the Editor of Dr. Molano-Triviño and Colleagues. <i>Blood Purification</i> , 2020, 49, 123-124.	1.8	0
568	Does really central venous pressure affect the risk of diuretic-associated acute kidney injury after cardiac surgery?. <i>American Heart Journal</i> , 2020, 226, 252.	2.7	0
569	Race and Place in ESKD. <i>Kidney International Reports</i> , 2021, 6, 252-253.	0.8	0
570	Self-care training using the Tablo hemodialysis system. <i>Hemodialysis International</i> , 2021, 25, 12-19.	0.9	0
571	The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis. <i>CardioRenal Medicine</i> , 2021, 11, 174-183.	1.9	0
572	MO518INSIDE CKD: MODELLING THE ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE IN THE AMERICAS AND THE ASIA-PACIFIC REGION USING PATIENT-LEVEL MICROSIMULATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
573	Patient-Reported Experiences with Dialysis Care and Provider Visit Frequency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1052-1060.	4.5	0
574	AUTHOR REPLY. <i>Urology</i> , 2021, 155, 76.	1.0	0
575	The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
576	Abstract P145: Screening Rates for the Diagnostic Workup of Resistant Hypertension. <i>Hypertension</i> , 2017, 70, .	2.7	0

#	ARTICLE	IF	CITATIONS
577	Testing two (of several) intravenous iron dosing strategies in hemodialysis. <i>Annals of Translational Medicine</i> , 2019, 7, S129-S129.	1.7	0
578	Obesity and Incident Kidney Disease: Busting the Myth of Metabolically Healthy Obesity. <i>American Journal of Kidney Diseases</i> , 2021, , .	1.9	0
579	Association of Apolipoprotein L-1 polymorphisms with blood pressure in three multi-ethnic African studies. <i>Journal of Global Health Reports</i> , 0, , .	1.0	0
580	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
581	MO536: Cardiovascular Events in Patients With Anemia Associated With Nonâ€“Dialysis-Dependent Chronic Kidney Disease: Regional Analysis of Patients not Previously Treated With Erythropoiesis-Stimulating Agents in The PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
582	MO532: Cardiovascular Events in Patients With Nonâ€“Dialysis-Dependent Chronic Kidney Disease and Anemia: Regional Analysis of Patients Previously Treated With Erythropoiesis-Stimulating Agents in the PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
583	Reply. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1093-1094.	2.9	0